Anglia Ruskin Research Online (ARRO)
Journal of Medical Virology - 2024 - Woo - Global burden of vaccine‐associated multiple sclerosis 1967 2022 A.pdf (1.4 MB)

Global burden of vaccine-associated multiple sclerosis, 1967–2022: a comprehensive analysis of the international pharmacovigilance database

Download (1.4 MB)
journal contribution
posted on 2024-04-19, 10:32 authored by Ho Geol Woo, Hyeon Jin Kim, Jaeyu Park, Jinseok Lee, Hayeon Lee, Min Seo Kim, Ai Koyanagi, Lee Smith, Masoud Rahmati, Seung Geun Yeo, Dong Keon Yon

Vaccine-associated multiple sclerosis (MS) is rare, with insufficient evidence from case reports. Given the scarcity of large-scale data investigating the association between vaccine administration and adverse events, we investigated the global burden of vaccine-associated MS and potential related vaccines from 1967 to 2022. Reports on vaccine-associated MS between 1967 and 2022 were obtained from the World Health Organization International Pharmacovigilance Database (total number of reports = 120 715 116). We evaluated global reports, reporting odds ratio (ROR), and information components (IC) to investigate associations between 19 vaccines and vaccine-associated MS across 156 countries and territories. We identified 8288 reports of vaccine-associated MS among 132 980 cases of all-cause MS. The cumulative number of reports on vaccine-associated MS gradually increased over time, with a substantial increase after 2020, owing to COVID-19 mRNA vaccine-associated MS. Vaccine-associated MS develops more frequently in males and adolescents. Nine vaccines were significantly associated with higher MS reporting, and the highest disproportional associations were observed for hepatitis B vaccines (ROR 19.82; IC025 4.18), followed by encephalitis (ROR 7.42; IC025 2.59), hepatitis A (ROR 4.46; IC025 1.95), and papillomavirus vaccines (ROR 4.45; IC025 2.01). Additionally, MS showed a significantly disproportionate signal for COVID-19 mRNA vaccines (ROR 1.55; IC025 0.52). Fatal clinical outcomes were reported in only 0.3% (21/8288) of all cases of vaccine-associated MS. Although various vaccines are potentially associated with increased risk of MS, we should be cautious about the increased risk of MS following vaccination, particularly hepatitis B and COVID-19 mRNA vaccines, and should consider the risk factors associated with vaccine-associated MS.



  • Yes



Issue number


Publication title

Journal of Medical Virology





File version

  • Published version

Item sub-type


Affiliated with

  • School of Psychology and Sport Science Outputs